GEREF (sermorelin acetate) — Adverse Reactions, US prescribing information (FDA revision 10/2/2001), reproduced by RxList
Serono Laboratories / RxList (WebMD) · 2001rxlist.com
Repeated subcutaneous treatment: the most common treatment-related adverse event, in about 1 patient in 6, is a local injection reaction of pain, swelling or redness. Other treatment-related events occurred individually at under 1% — headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria. Intravenous diagnostic use: flushing of the face, injection site pain, redness and/or swelling, nausea, headache, vomiting, dysgeusia, pallor and tightness in the chest. A large proportion of patients develop anti-GRF antibodies at least once during treatment. GEREF was discontinued in the US in 2008 and FDA no longer hosts the label for either NDA 19-863 or NDA 20-443; this is a publisher's reproduction of it, not an FDA-hosted document.